MATINAS BIOPHARMA HOLDINGS, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2024-03-27
- MATINAS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-27 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2021-12-31 | $0.00 10-K/A · filed 2022-03-11 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |